Keep tabs on your favorite ETFs with a personalized weekly tracker. Create a Watchlist now →
Crossmark Large Cap Growth ETF (CLCG) belongs to the US Large Cap Growth segment. NYLI U.S. Large Cap R&D Leaders ETF (LRND) is part of the US Large Cap segment. CLCG's top 3 sector exposures are Information Technology, Communication Services and Financials. In contrast, LRND's top sector exposures are Information Technology, Communication Services and Health Care. CLCG is more expensive with a Total Expense Ratio (TER) of 0.5%, versus 0.15% for LRND. CLCG is down -4.75% year-to-date (YTD) with +$2M in YTD flows. LRND performs better with -3.22% YTD performance, and +$102M in YTD flows. Run a side-by-side ETF comparison of CLCG and LRND below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.
| 1M | 3M | YTD | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|---|---|
| Perf. | CLCG LRND | -2.10%-1.96% | -5.90%-4.33% | -4.75%-3.22% | n/a+20.86% | n/a+94.41% | n/an/a |
| Flows | CLCG LRND | +$1M+$54M | +$3M+$159M | +$2M+$102M | -+$160M | -+$161M | -- |
| 3M | 1Y | 3Y | 5Y | ||
|---|---|---|---|---|---|
| Volatility | CLCG LRND | +17.64%+15.11% | n/a+20.81% | n/a+17.14% | n/an/a |
| Max drawdown | CLCG LRND | -7.76%-5.64% | n/a-16.04% | n/a-20.97% | n/an/a |
| Max drawdown duration | CLCG LRND | 72d41d | n/a49d | n/a126d | n/an/a |
CLCG | LRND | |
Last sale 3/12/2026 at 1:46 PM | $25.65 | $39.31 |
| Previous close 03/11/2026 | $25.65 | $39.42 |
| Consolidated volume 03/11/2026 | ||
| Average volume 30 days | ||
| Average discount or premium 30 days | ||
| Average Bid/Ask spread 30 days |
Create an account to view replication metrics
CLCG | LRND | |
|---|---|---|
| Tracking error | ||
| Tracking difference | ||
| 1 year cumulative return difference | ||
| Best | ||
| Worst | ||
| Daily return difference | ||
| Average | ||
| Worst | ||
CLCG | LRND | |
|---|---|---|
| Last price | $25.65 | $39.31 |
| 1D performance | +0.00% | -0.27% |
| AuM | $23.63 M | $165.63 M |
| E/R | 0.5% | 0.15% |
CLCG | LRND | |
|---|---|---|
| Management strategy | Active | Passive |
| Provider | Crossmark Global Investment | New York Life Investments |
| Benchmark | - | NYLI U.S. Large Cap R&D Leaders Index |
| N° of holdings | 27 | 93 |
| Asset class | - | Equities |
| Trailing 12m distribution yield | Join | Join |
| Inception date | July 23, 2025 | February 8, 2022 |
| ESG | No | No |
Total weight of top 15 holdings out of 15
Total weight of top 15 holdings out of 15
Join J.P. Morgan’s Bram Kaplan, Head of Americas Equity Derivatives Strategy and Matt Kaufman from Calamos Investments as they dive into the growing global opportunity in autocallable income—an increasingly dominant strategy within structured products, now available through ETFs.
Accepted for 1 CE Credit
